Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jacob Korula

Gastroenterology Arcadia, CA Medical Doctor

NPI 1295732568 CMS profile 285145

622 W Duarte Rd, Suite 302, Arcadia, CA 91007

Open in the dashboard

General payments

$3,920

78 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jacob Korula of Arcadia, CA is reported in the CMS Open Payments database as having received $3,920 across 78 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 61st percentile of Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $230 11
2024 General $381 11
2023 General $110 5
2022 General $65 6
2021 General $218 12
2020 General $2,370 15
2019 General $546 18

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jacob Korula
  • Gastroenterology median
  • Middle half of Gastroenterology
  • National median

In program year 2025, general payments to Jacob Korula were reported at $230. Among 13,050 Gastroenterology profiles paid that year, the median was $639 and the middle half received between $167 and $1,700.

Show as a table
Year Jacob Korula Gastroenterology median Middle half National median
2019 $546 $417 $126–$1,100 $163
2020 $2,370 $224 $74–$624 $114
2021 $218 $352 $106–$1,054 $132
2022 $65 $448 $129–$1,270 $149
2023 $110 $533 $150–$1,390 $160
2024 $381 $605 $160–$1,606 $164
2025 $230 $639 $167–$1,700 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Gilead Sciences, Inc. $2,681 28 payments
  2. Salix Pharmaceuticals, a division of Bausch Health US, LLC $268 15 payments
  3. AbbVie, Inc. $253 7 payments
  4. Dova Pharmaceuticals $200 4 payments
  5. CVRx, Inc. $169 1 payment
  6. Exact Sciences Corporation $81 4 payments
  7. Intercept Pharmaceuticals, Inc. $69 3 payments
  8. Merck Sharp & Dohme Corporation $43 2 payments
  9. Blueprint Medicines Corporation $38 1 payment
  10. Eisai Inc. $25 1 payment
  11. Other $92 12 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $2,230 1 payment
  2. Food and Beverage $1,674 69 payments
  3. Education $16 8 payments
Products named General payments · program years 2019–2025
  1. Vemlidy $2,230 1 payment
  2. XIFAXAN $256 14 payments
  3. Doptelet $200 4 payments
  4. Barostim Neo System $169 1 payment
  5. CREON $133 6 payments
  6. MAVYRET $120 1 payment
  7. LINZESS $115 5 payments
  8. OCALIVA $50 2 payments
  9. Cologuard Collection Kit $47 2 payments
  10. ZINPLAVA $43 2 payments
  11. Other $271 20 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 20 drugs

Part D claims

412

Median for Gastroenterology: 569

Drug cost

$117,938

Median for Gastroenterology: $104,976

Branded share of claims

28.9%

Median for Gastroenterology: 31.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Xifaxan Rifaximin Brand 15 $48,176
Vemlidy Tenofovir Alafenamide Brand 32 $45,479
Mesalamine Generic 11 $5,359
Ursodiol Generic 49 $5,321
Entecavir Generic 17 $5,149
Dexlansoprazole Dr Dexlansoprazole Brand 11 $2,563
Lamivudine Hbv Lamivudine Brand 18 $1,794
Sod Sulf-Potass Sulf-Mag Sulf Sodium, Potassium,mag Sulfates Brand 17 $1,131
Famotidine Generic 24 $468
Pantoprazole Sodium Generic 54 $464

The 10 drugs with the highest cost, of 20 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,294 Part D prescribers listed as Gastroenterology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 27 billing codes

Paid by Medicare

$104,602

Medicare's payments for the services billed

Medicare patients

306

Average age 74

Services billed

1,202

177 women, 129 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 62%
Diabetes 56%
Chronic kidney disease 44%
Heart failure 39%
Ischemic heart disease 38%
Depression 25%
COPD 23%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

3 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
XIFAXAN
  • Salix Pharmaceuticals, a division of Bausch Health US, LLC $77
$77 15 —
OCALIVA
  • INTERCEPT PHARMACEUTICALS, INC. $24
$24 — —
RESMETIROM
  • Madrigal Pharmaceuticals $22
$22 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

78 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gastroenterology in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record